Mark Krul

Chief Executive Officer

Mark Krul has been a Board member of Inthera since 2015. Mark has been involved in anticancer drug development since 1993 and has a background in molecular biology and immunology. He is co-founder of a number of biotech companies and is an active board member of several portfolio companies of Aglaia Oncology Funds, an investment fund he started in 2003. He currently also is part-time CSO of Oncode Accelerator, a growth fund of the Dutch Government focused on innovating preclinical cancer drug development. Before founding Aglaia he was Program Director of the NDDO Research Foundation. He held several positions with NDDO Oncology BV (formerly the EORTC New Drug Development Office) with respect to oncology drug development strategies (1997-2002). From 1993 until 1997 Mark was Research Manager of the European Cancer Center and headed the Department of Molecular Virology at the National Institute of Public Health and Environmental Protection from 1989 until 1993.